147 related articles for article (PubMed ID: 15989709)
1. Revisiting the use of recombinant erythropoietin in myelodysplastic syndromes.
Musto P
Clin Lymphoma; 2005 Jun; 6(1):52-5. PubMed ID: 15989709
[No Abstract] [Full Text] [Related]
2. Clinical use of growth factors in the myelodysplastic syndromes.
Stein RS
Am J Med Sci; 1994 May; 307(5):360-7. PubMed ID: 7513498
[No Abstract] [Full Text] [Related]
3. Erythropoietin, with and without granulocyte-colony stimulating factor (G-CSF), in the treatment of myelodysplastic syndrome (MDS) patients.
Miller K
Leuk Res; 1998 May; 22 Suppl 1():S13-6. PubMed ID: 9734694
[No Abstract] [Full Text] [Related]
4. Combined use of erythropoietin and G-CSF in the treatment of myelodysplastic syndromes.
Haematologica; 1999 Dec; 84(12):1057. PubMed ID: 10586204
[No Abstract] [Full Text] [Related]
5. A strategy for erythropoietin treatment in myelodysplastic syndromes.
Hast R
Med Oncol; 1999 Sep; 16(3):188-90. PubMed ID: 10523798
[No Abstract] [Full Text] [Related]
6. Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodysplastic syndromes.
Imamura M; Kobayashi M; Kobayashi S; Yoshida K; Mikuni C; Ishikawa Y; Matsumoto S; Sakamaki S; Niitsu Y; Hinoda Y
Ann Hematol; 1994 Apr; 68(4):163-6. PubMed ID: 7516190
[TBL] [Abstract][Full Text] [Related]
7. Dramatic hyperleukocytosis after treatment of myelodysplastic syndrome with pegfilgrastim and darbepoetin-alfa.
Heydrich BN; Schoch R; Horst HA; Kneba M
Ann Hematol; 2008 Jan; 87(1):77-8. PubMed ID: 17710399
[No Abstract] [Full Text] [Related]
8. Clinical application of recombinant erythropoietin in myelodysplasia.
Mittelman M; Lessin LS
Hematol Oncol Clin North Am; 1994 Oct; 8(5):993-1009. PubMed ID: 7852220
[TBL] [Abstract][Full Text] [Related]
9. Treatment of anemia in myelodysplastic syndrome with darbepoetin and granulocyte colony stimulating factor.
Rose S; Ali Y; Maffei B; Saidi P
Am J Hematol; 2007 Mar; 82(3):245-6. PubMed ID: 16924646
[No Abstract] [Full Text] [Related]
10. Comparison of rHuEpo plus rHuG-CSF and supportive care: apples to oranges.
Stasi R; Amadori S; Newland AC; Provan D
Blood; 2004 Oct; 104(7):2201; author reply 2201-2. PubMed ID: 15377575
[No Abstract] [Full Text] [Related]
11. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin.
Mantovani L; Lentini G; Hentschel B; Wickramanayake PD; Loeffler M; Diehl V; Tesch H
Br J Haematol; 2000 May; 109(2):367-75. PubMed ID: 10848827
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte colony-stimulating factor and erythropoietin for the anemia of myelodysplastic syndromes: a real improvement with respect to erythropoietin alone?
Musto P; Falcone A; Carotenuto M; Catalano L; Cennamo A; Rotoli B
Blood; 1994 Sep; 84(5):1687-8. PubMed ID: 7520783
[No Abstract] [Full Text] [Related]
13. Revisiting use of growth factors in myelodysplastic syndromes.
Newman K; Maness-Harris L; El-Hemaidi I; Akhtari M
Asian Pac J Cancer Prev; 2012; 13(4):1081-91. PubMed ID: 22799286
[TBL] [Abstract][Full Text] [Related]
14. Unusual clinical presentation in a patient with myelodysplastic syndrome, with subsequent hematological remission and suppression of the malignant clone following treatment with cyclosporine A, erythropoietin and granulocyte colony-stimulating factor.
Samuelsson J; Lärfars G
Leuk Res; 1999 May; 23(5):513-7. PubMed ID: 10374866
[TBL] [Abstract][Full Text] [Related]
15. Haemopoietic growth factors 2: clinical applications.
Metcalf D
Lancet; 1989 Apr; 1(8643):885-7. PubMed ID: 2564958
[No Abstract] [Full Text] [Related]
16. Treatment options for myelodysplastic syndromes.
Stone R
Cancer Control; 2004; 11(6 Suppl):7-10. PubMed ID: 15625531
[No Abstract] [Full Text] [Related]
17. Treatment of myelodysplastic syndromes with hematopoietic growth factors.
Ganser A; Hoelzer D
Hematol Oncol Clin North Am; 1992 Jun; 6(3):633-53. PubMed ID: 1377194
[TBL] [Abstract][Full Text] [Related]
18. [Effect of recombinant human G-CSF combined with EPO in treatment of patients with MDS].
Li ZY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):512-3. PubMed ID: 15972155
[TBL] [Abstract][Full Text] [Related]
19. In vitro study of erythropoiesis in patients with aplastic anemia and myelodysplastic syndromes: a possible tool for prospective determination of the clinical effectiveness of growth factors.
Aoki A; Shibata A
Hematol Pathol; 1992; 6(3):143-53. PubMed ID: 1429342
[TBL] [Abstract][Full Text] [Related]
20. [Clinical use of hematopoietic growth factors].
Robak T
Pol Tyg Lek; 1992 Apr 20-27; 47(16-17):365-8. PubMed ID: 1279638
[No Abstract] [Full Text] [Related]
[Next] [New Search]
